BIRC5 and breast carcinoma: The results showed that these NPs significantly downregulated hTERT, Bcl-2, cyclin D1, and survivin, while upregulating caspase-3, caspase-7, and Bax in breast cancer cells, thereby enhancing the antitumor therapeutic effect.